The most recent PARPi to be approved in ovarian cancer is niraparib, GlaxoSmithKline/Tesaro’s PARP inhibitor, ZejulaTM(1000 Winter St, Waltham, MA 02451, USA). This evidence concerns the gene PARP1 and ovarian cancer.